男友太凶猛1v1高h,大地资源在线资源免费观看 ,人妻少妇精品视频二区,极度sm残忍bdsm变态

Global EditionASIA 中文雙語Fran?ais
China
Home / China / Health

New vaccine protects the previously infected

By WANG XIAOYU | China Daily | Updated: 2021-09-24 09:59
Share
Share - WeChat
Taxi driver Zheng Ruiwen (front) puts on a protective gown before setting off to transport COVID-19 nucleic acid samples in Putian, Fujian province, on Sept 23, 2021. [Photo by ZHANG BIN/CHINA NEWS SERVICE]

Chinese biotechnology company Clover Biopharmaceuticals said on Wednesday that a large trial shows its two-dose COVID-19 vaccine is 79 percent effective against the fast-spreading Delta variant, which was first detected in India.

The vaccine candidate is 92 percent effective against the Gamma variant first identified in Brazil, and 59 percent against the Mu variant first detected in Colombia, according to joint statement issued by the company and the Coalition for Epidemic Preparedness Innovations, a nonprofit organization that funded the clinical trial.

The vaccine's overall efficacy rate against all strains in the study was 67 percent. It was also 100 percent effective in preventing severe cases and hospitalizations, and nearly 84 percent effective in preventing moderate to severe cases, the statement said.

The vaccine is the "first COVID-19 vaccine to demonstrate significantly reduced risk of COVID-19 disease in previously infected individuals, a growing and increasingly important population as SARS-CoV-2(the novel coronavirus that causes the disease) continues to spread globally", it said.

The protein-based vaccine uses protein fragments of the virus to trigger immune responses, and requires the use of an adjuvant to achieve desired protection.

Clover Biopharmaceuticals, which is based in Chengdu, Sichuan province, said its adjuvant is supplied by the US company Dynavax.

More than 30,000 adults-some of them elderly-in the Philippines, Brazil, Colombia, South Africa and Belgium were enrolled in mid- and late-stage clinical trials. They were either given two doses administered 21 days apart or a placebo.

Like the inactivated vaccines widely deployed in China, the experimental vaccine can be stored at regular refrigerated temperatures of 2 to 8 C, making its transportation and distribution easier.

The company said it plans to submit applications for conditional market approval to global regulatory authorities in the fourth quarter of the year and is aiming for a potential market launch by the end of the year.

Clover Biopharmaceuticals is also a supplier to COVAX, an international initiative that distributes vaccines to low- and middle-income countries.

The company signed an advance purchase agreement with Gavi, one of the co-leaders of COVAX, in late June to provide 414 million doses of its vaccine to the initiative by next year.

However, the product has to first gain emergency use authorization from the World Health Organization, which is anticipated in the fourth quarter of this year, according to Gavi.

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
 
主站蜘蛛池模板: 浦城县| 灯塔市| 浮梁县| 敦煌市| 福建省| 自治县| 普安县| 陕西省| 信宜市| 平凉市| 岚皋县| 易门县| 呼玛县| 伊春市| 达拉特旗| 泰州市| 依兰县| 启东市| 武川县| 南昌县| 抚宁县| 麦盖提县| 岳普湖县| 临夏市| 县级市| 临安市| 桃园市| 越西县| 白玉县| 济阳县| 临漳县| 盐亭县| 神农架林区| 梅河口市| 文水县| 阿合奇县| 炎陵县| 伊宁县| 张家界市| 连山| 阜新市|